Anavex (AVXL): Rasio rega marang pendapatan
The speculative nature of neurodrug development requires regulatory approval. Anavex Life Sciences focuses on the breakthrough application of Blarcamesine to combat Parkinson's and Alzheimer's diseases, scaling Phase 3 trials. The historical P/S trend confirms the sales value dynamics, where reflects the latest metric value. High scientific risks and fierce competition for leadership in brain degeneration therapy create significant business challenges.
Anavex Corp (AVXL) - rincian metrik lan laporan keuangan
- rega saham lan konsensus proyeksi valuasi:
- data kapitalisasi bursa:
- statistik nilai buku emiten:
- statistik kawajiban utang lan likuiditas:
Utang marang Modal Anavex Life Sciences|AVXL - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Anavex Life Sciences Corp|AVXL - Utang perusahaan|Utang-utang marang aset resik Anavex Corp|AVXL - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Anavex Life Sciences|Koefisien jangkoan perantara anavex.com
- data bathi resik lan rasio valuasi:
AVXL - Bathi resik|Bathi resik sing dikarepake Anavex Life Sciences|AVXL - Rasio rega marang bathi|Rasio rega marang bathi mangsa ngarep Anavex|AVXL - Pangali PEG|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Anavex Corp|AVXL - Bathi operasional EBITDA|Bathi resik saben siji saham sajrone rolas wulan pungkasan Anavex Life Sciences|AVXL - Bathi saben saham sajrone rolas wulan pungkasan|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan anavex.com|AVXL - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Anavex Life Sciences
- rincian pendapatan lan dodolan emiten:
Analisis fundamental perusahaan:AVXL, anavex.com
The P/S ratio determines the market value of one dollar of revenue, allowing for an assessment of the premium paid for a business relative to its current operating income. By analyzing the price-to-sales ratio, an investor can gauge market expectations for the monetization of Anavex Life Sciences (AVXL) patents, where a high valuation is driven by long-term demand for neurodegenerative disease therapies.
Perusahaan pesaing
BIIB (biogen.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Neurocrine Biosciences, Inc. NBIX|Regencell Bioscience Ltd - Rasio rega marang pendapatan|Axsome Therapeutics Inc - Multiplikator P/S|Koefisien rega marang pendapatan ACADIA Corp ACAD|XENE: Multiplikator P/S|Rasio rega marang dodolan VKTX (vikingtherapeutics.com)|SUPN (Supernus) - Multiplikator P/S|Rega marang dodolan Catalyst Pharma CPRX|Kapitalisasi marang pendapatan DNLI (Denali Therapeutics Inc)|HRMY (Harmony Corp) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Biohaven Ltd. BHVN|Koefisien rega marang pendapatan amylyx.com (AMLX)|Trevi Therapeutics, Inc. - Multiplikator P/S|Praxis Precision Medicines Inc (PRAX) - Kapitalisasi marang pendapatan|CBLL: Multiplikator P/S|PRTA - Koefisien rega marang pendapatan|ALEC (Alector Inc.) - Multiplikator P/S|Rega marang dodolan annexonbio.com ANNX|Rasio rega marang pendapatan Omeros Corporation (OMER)|Neurogene Inc - Rasio kapitalisasi marang pendapatan|Multiplikator P/S ACIU (AC Immune Corp)|VYGR - Kapitalisasi marang pendapatan|Neumora Therapeutics - Multiplikator P/S|Rega marang dodolan scilexholding.com|Tevogen Bio (TVGN) - Rasio rega marang pendapatan|ACOG - Koefisien rega marang pendapatan|CGTX (Cognition Therapeutics, Inc.) - Multiplikator P/S|Multiplikator P/S Inhibikase Pharma|Kapitalisasi marang pendapatan SAVA (Cassava Sciences, Inc.)|Rasio rega marang pendapatan ASRT (assertiotx.com)|Coya Therapeutics - Kapitalisasi marang pendapatan|VTGN: Rasio kapitalisasi marang pendapatan|OVID - Rasio rega marang pendapatan|ABOS: Rasio rega marang pendapatan|CervoMed Inc. (CRVO) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan ATHE|CLNN (Clene Inc) - Multiplikator P/S|Rega marang dodolan PepGen Corp PEPG|Kapitalisasi marang pendapatan JUNS (Jupiter Neurosciences)|Multiplikator P/S Relmada Corp (RLMD)|Rasio rega marang pendapatan Annovis Bio, Inc. ANVS|Rasio kapitalisasi pasar marang pendapatan GRCE|AIFF - Rasio rega marang pendapatan|Rega marang dodolan Klotho Neurosciences Inc|NRSN: Multiplikator P/S|Reviva Pharmaceuticals, Inc. (RVPH) - Multiplikator P/S|Rasio rega marang pendapatan MetaVia Inc.|Rasio kapitalisasi marang pendapatan NRXS (neuraxis.com)|Multiplikator P/S HSDT|Multiplikator P/S passagebio.com (PASG)|Neuphoria Therapeutics - Kapitalisasi marang pendapatan|Minerva - Rasio rega marang pendapatan|Athira Pharma, Inc. - Multiplikator P/S|Rega marang dodolan addextherapeutics.com|ALZN (alzamend.com) - Kapitalisasi marang pendapatan|Rasio kapitalisasi marang pendapatan CYCN|Kapitalisasi marang pendapatan PTIX|KTTA: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Cortigent, Inc. (CRGT)|Rasio rega marang pendapatan ATXI (avenuetx.com)|Multiplikator P/S BCLI (BrainStorm Cell Therapeutics)|Koefisien rega marang pendapatan Cara Therapeutics Inc. (CARA)|Chromocell Therapeutics Corporation - Multiplikator P/S|Rasio rega marang dodolan ELYM|ITCI: Multiplikator P/S|Rega marang dodolan longboardpharma.com (LBPH)|Kapitalisasi marang pendapatan MRNS|NKGN: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan NeuroBo (NRBO)|Koefisien rega marang pendapatan Sage Therapeutics Inc|Multiplikator P/S SNPX (Synaptogenix, Inc.)|TRVN - Kapitalisasi marang pendapatan|Vigil Neuro - Multiplikator P/S|Koefisien rega marang pendapatan anewmeds.com WENA|CERE: Multiplikator P/S
